Dermapharm Holding SE (VIE:DMP)
| Market Cap | 1.62B -14.6% |
| Revenue (ttm) | 1.18B +1.7% |
| Net Income | 130.35M +12.3% |
| EPS | 2.52 +17.1% |
| Shares Out | n/a |
| PE Ratio | 13.18 |
| Forward PE | 10.81 |
| Dividend | 0.88 (2.65%) |
| Ex-Dividend Date | Jun 29, 2026 |
| Volume | n/a |
| Open | 33.20 |
| Previous Close | 33.45 |
| Day's Range | 33.15 - 33.40 |
| 52-Week Range | 33.25 - 51.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company a... [Read more]
Financial Performance
In 2025, Dermapharm Holding SE's revenue was 1.17 billion, a decrease of -1.32% compared to the previous year's 1.18 billion. Earnings were 132.41 million, an increase of 16.37%.
Financial StatementsNews
Dermapharm Holding SE Earnings Call Transcript: Q3 2026
9M revenue grew 1.7% to €884 million, with 2.3% organic growth led by branded products; Q3 adjusted EBITDA fell ~€3 million YoY, largely on lower BioNTech contribution. Operating cash flow rose 10%, and FY 2026 guidance was confirmed.
Dermapharm Holding SE Quarterly report: Q3 2026
Dermapharm Holding SE has published its Q3 2026 quarterly earnings report on November 12, 2026.
Dermapharm Holding SE Slides: Q3 2026
Dermapharm Holding SE has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 12, 2026.
Dermapharm Holding SE Earnings release: Q3 2026
Dermapharm Holding SE released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
Dermapharm Holding: Branded Pharma Strength Drives Positive Results
Branded medicines fuelled Dermapharm’s growth in the first nine months of 2026, lifting revenue and profitability as the group reaffirmed its full-year outlook.
EQS-AFR: Dermapharm Holding SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
EQS Preliminary announcement financial reports: Dermapharm Holding SE / Preliminary announcement on the disclosure of financial statements Dermapharm Holding SE: Preliminary announcement of the public...
Dermapharm Holding SE Earnings Call Transcript: Q2 2026
Strong H1 2026 performance driven by branded and international growth, with revenue up 5% and adjusted EBITDA up 14%. Guidance for FY 2026 is confirmed, with continued momentum expected in key segments and no material regulatory impact anticipated.
Dermapharm Holding SE Earnings release: Q2 2026
Dermapharm Holding SE released its Q2 2026 earnings on August 25, 2026, summarizing the period's financial results.
Dermapharm Holding SE Slides: Q2 2026
Dermapharm Holding SE has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 25, 2026.
Dermapharm Holding SE Quarterly report: Q2 2026
Dermapharm Holding SE has published its Q2 2026 quarterly earnings report on August 25, 2026.
EQS-AFR: Dermapharm Holding SE: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: Dermapharm Holding SE / Preliminary announcement on the disclosure of financial statements Dermapharm Holding SE: Preliminary announcement of the public...
Dermapharm Holding SE Earnings Call Transcript: Q1 2026
Q1 2026 delivered 1.1% revenue growth and a 7.5% rise in adjusted EBITDA, with margin expansion and strong free cash flow. All segments contributed, Mucos integration advanced, and the share buyback reduced free float to just above 10%.
Dermapharm Holding SE Slides: Q1 2026
Dermapharm Holding SE has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Dermapharm Holding SE Quarterly report: Q1 2026
Dermapharm Holding SE has published its Q1 2026 quarterly earnings report on May 13, 2026.
Dermapharm Holding SE Earnings Call Transcript: Q4 2025
Revenue and adjusted EBITDA for 2025 met guidance, with margin improvements and strong cash flow. Growth is expected in 2026 from M&A, branded products, and international expansion, while restructuring and portfolio optimization continue to drive efficiency.
Dermapharm Holding SE Annual report: Q4 2025
Dermapharm Holding SE has published its Q4 2025 annual report on March 31, 2026.
Dermapharm Holding SE Annual report: Q4 2025
Dermapharm Holding SE has published its Q4 2025 annual report on March 31, 2026.
Dermapharm Holding SE Earnings release: Q4 2025
Dermapharm Holding SE released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Dermapharm Holding SE Slides: Q4 2025
Dermapharm Holding SE has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 31, 2026.